Advances in the systemic therapy of malignant pleural mesothelioma

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 3, 2008, Pages 136-147

  Fennell, Dean A ^a   Gaudino, Giovanni ^b   O'Byrne, Kenneth J ^c   Mutti, Luciano ^d   van Meerbeeck, Jan ^e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c ST JAMES S HOSPITAL   (Ireland)

^d Department of General Medicine   (Italy)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Biomarkers; Chemotherapy; Mesothelioma; Novel therapy; Pleural

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC ANTIMETABOLITE; ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; DEPSIPEPTIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; FLAVOPIRIDOL; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MITOMYCIN; MITOXANTRONE; NAVELBINE; PEMETREXED; PLATINUM DERIVATIVE; RALTITREXED; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VORINOSTAT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; FOLIC ACID ANTAGONIST; PLACEBO; PROTEOME; VINDESINE;

CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG DESIGN; DRUG FATALITY; HUMAN; MALIGNANT MESOTHELIOMA; MONOTHERAPY; PATIENT CARE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC THERAPY; THORAX CANCER; BIOCHEMISTRY; CANCER CELL; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOLOGY; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; GLIOBLASTOMA; LUNG SURGERY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAIN; PROTEIN TARGETING; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; TREATMENT DURATION; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FOLIC ACID ANTAGONISTS; GENE EXPRESSION PROFILING; HUMANS; MESOTHELIOMA; PLATINUM COMPOUNDS; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 40249088552     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1089     Document Type: Review

References (81)

1. Hodgson JT et al. (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92 587-593
2. Flores RM (2005) The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 49 (Suppl 1): S27-S32
3. Berghmans T et al. (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: A systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121
4. Ellis P et al. (2006) The use of chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and practice guideline. J Thorac Oncol 1: 591-601
5. van Meerbeeck JP et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889
6. Vogelzang NJ et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644
7. Fennell DA and Rudd RM (2004) Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: Opportunities for effective drug development. Lancet Oncol 5: 354-362
8. Byrne MJ and Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15: 257-260
9. Oxnard GR et al. (2006) Modeling of mesothelioma growth demonstrates weaknesses of current response criteria. Lung Cancer 52: 141-148
10. Francart J et al. (2006) Progression-free survival rate as primary end point for phase II cancer clinical trials: Application to mesothelioma. The EORTC Lung Cancer Group. J Clin Oncol 24: 3007-3012
11. O'Brien ME et al. (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: The MED trial. Ann Oncol 17 270-275
12. Muers MF et al. (2004) BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112. Thorax 59: 144-148
13. Andreopoulou E et al. (2004) The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. Ann Oncol 15: 1406-1412
14. Steele JP et al. (2000) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18: 3912-3917
15. Green J et al. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Cochrane Database Systematic Reviews 2007, Issue 1. Art No.:CD005574. doi:10.1002/14651858.CD005574.pub2.
16. Bottomley A et al. (2006) Short-term treatment-related symptoms and quality of life: Results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 24: 1435-1442
17. Weder W et al. (2004) Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22: 3451-3457
18. Sugarbaker DJ et al. (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesotheliorna: Results in 183 patients. J Thorac Cardiovasc Surg 117: 54-63
19. MARS (mesothelioma and radical surgery) trial. http://pfsearch.ukcrn.org.uk/StudyDetail.aspx?TopicID=1&StudyID=1189
20. Zucali PA and Giaccone G (2006) Biology and management of malignant pleural mesothelioma. Eur J Cancer 42: 2706-2714
21. Fennell DA et al. (2007) Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 109: 93-99
22. Nagel S et al. (2005) Second-line treatment of malignant pleural mesothelioma with Pernetrexed (Alimta) - a case report. Pneumologie 59: 108-111
23. Giaccone G et al. (2002) Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 38 (Suppl 8): S19-S24
24. Manegold C et al. (2005) Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pernetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 16: 923-927
25. Sorensen JB et al. (2007) Pernetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2: 147-152
26. Jassem J et al. (2006) A randomized phase III trial comparing pernetrexed plus best supportive care (BSC) versus BSC in previously treated patients with advanced malignant pleural mesothelioma. Ann Oncol 17: Ix214
27. Spirtas R et al. (1988) Survival patterns for malignant mesothelioma: The SEER experience. Int J Cancer 41: 525-530
28. Herndon JE et al. (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723-731
29. Curran D et al. (1998) Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145-152
30. Fennell DA et al. (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23: 184-189
31. Edwards JG et al. (2000) Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems. Thorax 55: 731-735
32. Flores RM et al. (2006) Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132: 763-768
33. Ceresoli GL et al. (2006) Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose. J Clin Oncol 24: 4587-4593
34. Lopez-Rios F et al. (2006) Global gene expression profiling of pleural mesotheliomas: Overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66: 2970-2979
35. Ohta Y et al. (1999) Tumor angiogenesis and recurrence in stage I non-small cell lung cancer. Ann Thorac Surg 68: 1034-1038
36. Edwards JG et al. (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85: 863-868
37. Strizzi L et al. (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193: 468-475
38. Ohta Y et al. (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81: 54-61
39. Kumar-Singh S et al. (1999) Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189: 72-78
40. Klabatsa A et al. (2006) Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM). Lung Cancer 51: 53-59
41. Erler JT et al. (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889
42. Kokturk N et al. (2005) Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma. Lung Cancer 50: 189-198
43. Soini Y et al. (1999) Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 5: 3508-3515
44. O'Kane SL et al. (2006) Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol 45: 449-453
45. Segers K et al. (1994) Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium. Virchows Arch 424: 631-634
46. Narasimhan SR et al. (1998) Resistance of pleural mesothelioma cell lines to apoptosis: Relation to expression of Bcl-2 and Bax. Am J Physiol 275: L165-L171
47. Gordon GJ et al. (2003) Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95 598-605
48. Gordon GJ et al. (2005) Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 11: 4406-4414
49. Pass HI et al. (2004) Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 10: 849-859
50. Glinsky GV et al. (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521
51. Romano M et al. (2001) 5-lipoxygenase regulates malignant mesothelial cell survival: Involvement of vascular endothelial growth factor. Faseb J 15: 2326-2336
52. Hoang CD et al. (2004) Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: Association with distinct malignant phenotypes. Cancer Res 64: 7479-7485
53. Vogelzang NJ et al. (2005) New agents in the management of advanced mesothelioma. Semin Oncol 32: 336-350
54. Jagadeeswaran R et al. (2006) Functional analysis of c-Met/ hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 66: 352-361
55. Mukohara T et al. (2005) Inhibition of the met receptor in mesothelioma. Clin Cancer Res 11: 8122-8130
56. Catalano A et al. (2004) Induction of stem cell factor/c-Kit/slug signal transcluction in m ultidrug-resistant malignant mesotheliorna cells. J Biol Chem 279: 46706-46714
57. Cacciotti P et al. (2005) SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 65: 5256-5262
58. Ramos-Nino ME et al. (2005) Human mesothelioma cells exhibit tumor cell-specific differences in phosphaticlylinositol 3-kinase/AKT activity that predict the efficacy of Onconase. Mol Cancer Ther 4: 835-842
59. Pespeni MH et al. (2007) Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res 67: 2865-2871
60. Altomare DA et al. (2005) Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24: 6080-6089
61. Bertino P et al. (2007) Preliminary data suggestive of a novel translational approach to mesothelioma therapy: Imatinib mesylate with gemcitabine or pemetrexed. Thorax 62: 690-695
62. Shih T and Lindley C (2006) Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28: 1779-1802
63. Karrison T et al. (2007) Final analysis of a multi-centre, double blind, placebo controlled, randomized phase II trial of gemcitabine/ cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma [abstract #7526]. Proc Am Soc Clin Oncol Part 1 25
64. Wedge SR et al. (2005) AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400
65. Adnane L et al. (2005) Sorafenib (BAY 43-9006, Nexavar((R))), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612
66. Prenen H et al. (2006) Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12: 2622-2627
67. Motzer RJ et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24
68. Motzer RJ et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524
69. Fischer JR et al. (2006) Promoter methylation of RASSF1A, RARbeta and IDAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54: 109-116
70. Nguyen DM et al. (2004) Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 10: 1813-1825
71. Szlosarek PW et al. (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12: 7126-7131
72. Borczuk AC et al. (2007) Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene 26: 610-617
73. Fennell DA et al. (2007) BCL-2 family regulation by the 20S proteosome inhibitor bortezomib. Oncogene [doi:10.1038/ sj.onc.1210744]
74. Sartore-Bianchi A et al. (2007) Bortezomib inhibits nuclear factor-kappa B-dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13: 5942-5951
75. Gordon GJ et al. (2007) Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma. Cancer Chemother Pharmacol [doi: 10.1007/s00280-007-0500-1]
76. US National Institutes of Health. http://www.cancer.gov/search/ psrv.aspx?cid=9817&protocolsearchid=3540567
77. Hassan R et al. (2004) Mesothelin: A new target for immunotherapy. Clin Cancer Res 10: 3937-3942
78. Ho M et al. (2005) Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 11 3814-3820
79. Friedlander PL et al. (2003) Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 29: 321-330
80. Gattacceca F et al. (2002) Ad-IFN gamma induces anti proliferative and antitumoral responses in malignant mesothelioma. Clin Cancer Res 8: 3298-3304
81. Powell A et al. (2006) Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 52: 189-197